Effect of intravenous lidocaine infusion on long-term postoperative pain after spinal fusion surgery
Abdelrady Ibrahim, MD*, Mohamed Aly, MD, Waleed Farrag, MD

Abstract
Background: Intravenous lidocaine infusion is known to reduce postoperative pain for days or weeks beyond the infusion time, and plasma half-life in several types of surgical procedures.
Objectives: To evaluate the effect of intravenous (IV) lidocaine infusion on long term postoperative pain intensity for 3 months in patients undergoing spinal fusion surgery.
Study Design: Prospective randomized, double-blinded study.
Setting: Assiut University Hospital, Assiut, Egypt.
Methods: Forty patients undergoing spinal fusion surgery were randomized into 2 equal groups (n = 20 in each). Patients in the lidocaine group received IV lidocaine at a dosage of 2.0 mg/kg slowly before induction of anesthesia, followed by lidocaine IV infusion at a rate of 3.0 mg/kg/h until the end of surgery. Patients in the control group received an equal volume of normal saline. The following data were assessed: pain by Visual Analog Score (VAS) at 1 hour, 6 hours, 12 hours, 24 hours, 48 hours, at discharge time, and at 1 month, 2 months, and 3 months post-operation, time to first request for additional analgesia, and total morphine consumption in 24 hours.
Results: Lidocaine significantly reduced the postoperative pain score (VAS) for up to 3 months (P < .05), and significantly reduced morphine consumption (4.5 mg vs. 19.85 mg) in the 1st 24 hours postoperative. Lidocaine also significantly prolonged (P < .05) the time to first request for additional analgesia (9.56 ± 2.06 hours vs 1.82 ± 0.91 hours).
Conclusion: Intra-operative lidocaine, when given intravenously as a bolus followed by an infusion, significantly decreased long term postoperative back pain intensity in patients undergoing spinal fusion surgery.
Abbreviations: μM/L = micromoles/L, ASA = American Society of Anesthesiologist, FBSS = failed back surgery syndrome, IV = intravenous, LA = local anesthetic, MEGX = mono-ethyl-glycine-xylidide, SD = Standard deviation, VAS = Visual Analog Score.
Keywords: lidocaine intravenous, long term back pain, spinal fusion

1. Introduction
Spinal fusion is a painful surgery, and control of postoperative pain is difficult. Several studies have indicated that appropriate pain treatment protocols reduce postoperative morbidity, improve the results of the surgery, and decrease hospital costs.[1] 

A likely, common mechanism for many adverse outcomes in patients with spinal fusion surgery is the systemic inflammatory response to surgical tissue injury.[2] In addition, the activation of glial cells in the surgical wound stimulates the production of cytokines in the central nervous system, which can induce peripheral, and central sensitization through generation of nitric oxide, free radicals, and excitatory amino acids, possibly also causing chronic, and neuropathic pain.[1] The role of inflammatory cytokines is also well recognized in the process of secondary hyperalgesia, and central sensitization.[1][4]

Obtaining adequate analgesia after major surgery is a problematic issue, and postoperative pain still imposes a major burden of suffering on surgical patients. Intravenous (IV) patient-controlled opioids the mainstay modality in acute surgical pain treatment, expose the patients to potentially serious side effects.[5]

Lidocaine which developed in the year 1948 is the first amino amide-type short-acting local anesthetic (LA). Originally, it was used mainly via the IV route as an antiarrhythmic drug. Lidocaine has a very short half-life, and a favorable safety profile, and is therefore the LA of choice for continuous IV administration.[6]

The perioperative administration of systemic IV lidocaine has been shown to be an effective method in postoperative pain management with a favorable effect on pain scores, opioid consumption (opioid-sparing effects), and recovery after surgery without any clear evidence of harm.[5]
Lidocaine has analgesic, and anti-inflammatory effects that are induced by reduction of cytokines production through inhibition of neutrophil activation, and the analgesia may persist even after plasma concentration reduction. Lidocaine IV administration produces an analgesic effect in various pain states, such as acute postoperative pain, and neuropathic pain. Lidocaine infusion has been shown to be successful in controlling pain, whereas other agents have failed. The opioid sparing properties of IV lidocaine infusion added to its analgesic, and anti-hyperalgesic properties make lidocaine infusion a viable option for pain control in chronic opioid users. Lidocaine group (n = 22) patients received a loading dose of IV lidocaine 2 mg/kg slowly just before induction of anesthesia, then the lidocaine infusion started at a rate of 3 mg/kg.h Control group (n = 22) patients received an equal volume of 0.9% sodium chloride (both the loading, and the infusion).

The infusion in both groups was initiated at the time of anesthesia induction, and continued until the end of the operation.

2.5. Anesthesia technique
General anesthesia was induced by propofol 2.5 mg/kg, and cisatracurium 0.15 mg/kg to facilitate orotracheal intubation. Patients were then assigned to either the lidocaine, or control group by closed-envelope randomization. In both the groups, anesthesia was maintained with isoflurane in oxygen/air mixture at sufficient concentration to maintain systolic blood pressure within the limit of 20% baseline value. All patients received 60 mg ketorolac IV infusion after induction of anesthesia, and fentanyl 1.5 μg/kg IV before skin incision. Acetaminophen (paracetamol) 1 gm was given by IV infusion to all patients before extubation. Reversal of residual muscle relaxant was accomplished using neostigmine, and atropine at the end of the operation. Patients were monitored with continuous electrocardiography, and pulse oximetry, and intermittent non-invasive blood pressure measurements every 5 minutes.

2.6. Postoperative pain control
In the first 24 hours postoperative; patients were given Ketorolac 30 mg slowly IV (diluted to 10 mL), and paracetamol 1 g injection for 8 hours. Morphine 0.1 mg/kg slowly IV was given as rescue analgesia when VAS was ≥4, or if the patient requested additional analgesia. A maximum of 3 doses of IV morphine were prescribed, with a minimum 8 hours interval between the 2 consecutive injections. After 24 hours post-operation; paracetamol 1 g, and ketorolac 10 mg for 8 hours were given orally for 2 weeks.

2.7. Data collection
Patient’s characteristics, and surgical data including age, gender, weight, height, duration of surgery, and duration of hospital stay. Postoperative pain evaluation during rest was assessed by VAS (0 = no pain, 10 = most severe pain). The score was recorded at the following times: immediately at 1 hour; 6 hours; 12 hours; 24 hours; at discharge time; 1 month; 2 months, and 3 months post-operation. Time to the first request for analgesia, and the total dose of rescue analgesia (morphine) in the first 24 hours after surgery was recorded. The long-term follow-up of postoperative back pain for 3 months was conducted through the outpatient orthopaedic clinic, or by telephone.

2.8. Sample size calculation
A sample size calculation was performed based on a previous study. To be able to detect a significant difference in pain score of 2 between the 2 groups. With an estimated standard deviation (SD) of 2.2, and an α of 0.05 in 20 patients of each group would yield 80% power. Four cases were added to the sample size to compensate for violation of the study protocol, or potential dropouts.
2.9. Statistical analysis

Collected data were analyzed using the statistical package IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp. Data with continuous variables were expressed as mean ± SD, and compared using a paired t-test, if normally distributed, and by Mann–Whitney U test, if not normally distributed. Differences were considered statistically significant if a P value <.05 was obtained.

3. Results

Forty four patients were enrolled in the study, randomly allocated to 2 groups, with 22 patients in each; 4 patients were excluded from the study. One patient in the lidocaine group developed convulsions during injection of the loading dose, and 1 refused to complete the study; while in control group 2 patients refused to complete the study as shown CONSORT Statement for Reporting Trials.

3.1. Patient’s characteristics and operative data

There were no significant differences observed between lidocaine group, and control group (P > .05) for age, sex, weight, height, ASA classification, operative time, and type of operation (number of fusion levels).

3.2. Length of hospital stay

The mean values of hospital stay was significantly lower (P = .001) in the lidocaine group (3.15 ± 1.08 days) when compared to that of the control group (4.55 ± 1.31 days) as shown in Table 1. The mean value of total lidocaine dose given to each patient in lidocaine group was 210.9 ± 12.16 mg/h.

3.3. Visual analogue score

The mean values of postoperative VAS pain score were significantly lower in the lidocaine group in the first 48 hours post operation, and during the study period up to 3 months after the operation (P < .05). At the time of discharge from the hospital, mean VAS values were 1.05 ± 0.88 in the lidocaine group, and 1.00 ± 1.33 in the control group. Long term postoperative follow up of the patients for 3 months revealed that VAS pain remained significantly lower in lidocaine group (P < .05) as shown in Figure 1, and Table 2.

3.4. The time to first analgesic request

The mean time to first analgesic request was significantly longer in lidocaine group (9.56 ± 2.60 hours) while it was 1.82 ± 0.91 hours in the control group (P < .001). Rescue analgesia: the mean total dose of morphine consumed by the patients during the first 24 hours post operation in the lidocaine group (4.5 ± 5.37 mg) was significantly lower than that consumed in the control group (19.85 ± 8.96 mg) with P < .001.

4. Discussion

This study evaluated the effect of intra-operative IV infusion of lidocaine on long term postoperative pain by assessment of VAS pain score for 3 months after spinal fusion surgery compared to control group. The data revealed that VAS pain score were significantly lower in the lidocaine group in the first 48 hours post operation, at time of discharge from the hospital, and after 3 months from the operation. The VAS for postoperative 48 hours, and 3 months after discharge in both groups were statistically but not clinically significant; it was mild, or moderate pain. The mean values of time to first request of additional analgesia (morphine) were significantly longer in the lidocaine group than in control group, and consequently the mean total dose of IV morphine consumed by the patients in the first 24 hours post-operation were significantly lower in the lidocaine group.

Our data are consistent with other studies in which IV lidocaine was found to improve the early postoperative analgesia in different types of surgery, including complex spine surgery.[25]
pediatric fusion surgery, subtotal gastrectomy, laparoscopic abdominal gynecologic surgery, outpatient laparoscopy, inguinal hernioplasty, and upper abdominal surgery.

On the other hand, some studies have failed to demonstrate a significant analgesic effect of IV lidocaine during the postoperative period after laparoscopic renal surgery, abdominal hysterectomy, and total hip arthroplasty.

A likely, common mechanism for many adverse outcomes in patients with spinal fusion surgery is the systemic inflammatory response to surgical tissue injury. In addition, the activation of glial cells in the surgical wound stimulates the production of cytokines in the central nervous system, which can induce peripheral, and central sensitization through generation of nitric oxide, free radicals, and excitatory amino acids, possibly also causing chronic, and neuropathic pain. The role of inflammatory cytokines is also well recognized in the process of secondary hyperalgesia, and central sensitization.

The potent anti-inflammatory effects of IV lidocaine are mediated by inhibition of N-methyl-d-aspartate receptors, and by reduction of cytokine production through inhibition of neutrophil activation. The analgesia produced by lidocaine may persist after reduction in its plasma levels, favoring the theory of blockade in neuronal conduction. Lidocaine’s metabolite, mono-ethyl-glycine-xylidide (MEGX), may also exert an analgesic effect. Systemic lidocaine has been reported to reduce the MAC of inhalational anesthetics, postoperative pain, analgesic consumption, postoperative nausea, and vomiting, and the length of stay in hospital.

The peroperative administration of systemic IV lidocaine has been shown to be an effective method in postoperative pain management with a favorable effect on pain scores, and both intra- and postoperative opioid consumption, and recovery after surgery without any clear evidence of harm. Its effect may continue for days, or weeks, that is, beyond the infusion time, and plasma half-life, indicating that it may affect other targets in addition to voltage-gated sodium channels. This suggests lidocaine may act via a prevention of the hypersensitivity of the central, or peripheral nervous system, or both.

In neuropathic, or inflammatory pain animal models, IV lidocaine is thought to exert analgesic effects by blocking specific Na+ channels in injured nerves, or dorsal root ganglia (DRG), because these channels are more sensitive to lidocaine. An interesting work was conducted by Viola et al which studied the long-term effect of IV lidocaine infusion in patients with diabetic neuropathy, and they found that lidocaine infusion markedly reduced both pain severity, and quality at 14 to 28 days post infusion. Similarly, Aslam et al concluded that lidocaine infusion in a dose of 5 mg/kg/h for 2 hours is both effective, and safe in reducing the chronic intractable pain in both painful diabetic neuropathy, and non-painful diabetic neuropathy patients.

In this study patients in lidocaine group received a loading dose of IV lidocaine 2mg/kg slowly, just before induction of anesthesia, then a continuous infusion of 2mg/kg/h was associated with decreased VAS pain scores, and opioid consumption in the first 24 hours. Park et al investigated the effects of IV lidocaine on neuropathic pain of failed back surgery syndrome (FBSS) which the results from abnormal impulse originated from the dorsal root ganglion, and spinal cord. The authors found that 1 mg/kg, or 5 mg/kg of IV lidocaine, and placebo improved pain in patients with neuropathic pain attributable to FBSS, but the 5 mg/kg dose was significantly, more effective in some pain items (sharp, dull, and deep pain). Administration of IV bolus injection of 1.0 mg/kg lidocaine immediately, before induction of anesthesia, then a continuous infusion at a rate of 2 mg/kg/h had a significant postoperative analgesic effect in patients undergoing thyroid surgery.

5. Conclusion
Our results suggest the role of lidocaine infusion as adjuncts to general anesthesia, it significantly, decreased long term postoperative back pain intensity, and delayed, and reduced the need for rescue analgesics, in patients that undergoing spinal fusion surgery.

6. Limitations
Small sample size is a limitation of this study which may affect our results however this sample size was similar to other study, another limitation is serum level of lidocaine which was not measured in this study however the loading, and maintenance dose in the present study was similar to those in previous studies with no detectable side effects.

7. Recommendations
The authors recommend further studies to be performed on a larger sample size, and different doses may be used to detect an optimal lidocaine dose. The study recommends the intraoperative use of lidocaine IV infusion as an alternative mode of analgesia following spine surgery due to its long-term analgesic effect.

Author contributions
Conceptualization: A. Ibrahim, W.S. Farrag.
Data curation: A. Ibrahim, W.S. Farrag.
Formal analysis: A. Ibrahim, M.G. Aly, W.S. Farrag.
Investigation: M.G. Aly, W.S. Farrag.
Methodology: A. Ibrahim, M.G. Aly, W.S. Farrag.
Software: A. Ibrahim.
Visualization: W.S. Farrag.
Writing – original draft: A. Ibrahim, M.G. Aly.
Writing – review & editing: A. Ibrahim, M.G. Aly, W.S. Farrag.

References
[1] De Oliveira CMB, Iosy AM, Sakata RK. Intraoperative intravenous lidocaine. Rev Bras Anestesiol 2010;60:325–33.
[2] Farag E, Ghobrial M, Sessler DJ, et al. Effect of perioperative intravenous lidocaine administration on pain, opioid consumption, and quality of life after complex spine surgery. Anesthesiology 2013;119:932–40.
[3] Belin B, Shavit Y, Trabekin E, et al. The effects of postoperative pain management on immune response to surgery. Anesth Analg 2003; 97:822–7.
[4] Hu P, McLachlan EM. Macrophage and lymphocyte invasion of dorsal root ganglia after peripheral nerve lesions in the rat. Neuroscience 2002;112:23–38.
[5] Grassi P, Bregant GM, Crisman M. Systemic intravenous lidocaine for perioperative pain management: a call for changing indications in the package sheet. Heart Lung and Vessel 2014;6:137–8.
[6] Kranke P, Jokinen J, Pace NL, et al. Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery. Cochrane Database Syst Rev 2015;7: CD009642.
[7] De Oliveira CMB, Sakata RK, Slullitel A, et al. Effect of intraoperative intravenous lidocaine on pain and plasma interleukin-6 in patients undergoing hysterectomy. Braz J Anesthesiol 2015;65:92–8.
[8] Kurabe M, Furue H, Kohno T. Intravenous administration of lidocaine directly acts on spinal dorsal horn and produces analgesic effect: an in vivo patch-clamp analysis. Sci Rep 2016;6:26253.
[9] Kandil E, Melikman E, Adinoff B. Lidocaine infusion: a promising therapeutic approach for chronic pain. J Anesth Clin Res 2017;8:pii:697.
[10] Yon JH, Choi GJ, Kang H, et al. Intraoperative systemic lidocaine for pre-emptive analgesia in subtotal gastrectomy: a prospective, random-ized, double-blind, placebo-controlled study. Can J Surg 2014;57: 175–82.
[11] Reynolds RA, Legakis JE, Tweedie J, et al. Postoperative pain management after spinal fusion surgery: an analysis of the efficacy of continuous infusion of local anesthetics. Global Spine J 2013;3:7–14.
[12] Grady P, Clark N, Lenahan J, et al. Effect of intraoperative intravenous lidocaine on postoperative pain and return of bowel function after laparoscopic abdominal gynecologic procedures. AANA J 2012;80:282–8.
[13] De Oliveira GS Jr, Fitzgerald P, Streicher LF, et al. Systemic lidocaine to improve postoperative quality of recovery after ambulatory laparoscopic surgery. Anesth Analg 2012;115:626–7.
[14] Kang H, Kim BG. Intravenous lidocaine for effective pain relief after inguinal herniorrhaphy: a prospective, randomized, double-blind, placebo-controlled study. J Int Med Res 2011;39:435–45.
[15] Baral BK, Bhattacharai BK, Rahman TR, Singh A, Regmi R. Perioperative intravenous lidocaine infusion on postoperative pain relief in patients undergoing upper abdominal surgery. Nepal Med Coll J 2010;12:215–20.
[16] Wuetrich PY, Romero J, Burkhard FC, et al. No benefit from perioperative intravenous lidocaine in laparoscopic renal surgery: a randomised, placebo-controlled study. Eur J Anaesthesiol 2012;29: 537–43.
[17] Bryson GL, Charapov I, Krolczyk G, et al. Intravenous lidocaine does not reduce length of hospital stay following abdominal hysterectomy. Can J Anaesth 2010;57:759–66.
[18] Martin F, Chenf K, Gentili ME, et al. Lack of impact of intravenous lidocaine on analgesia, functional recovery, and nociceptive pain threshold after total hip arthroplasty. Anesthesiology 2008;109:118–23.
[19] Kuo CP, Jao SW, Chen KM, et al. Comparison of the effects of thoracic epidural analgesia and i.v infusion with lidocaine on cytokine response, postoperative pain and bowel function in patients undergoing colonic surgery. Br J Anaesth 2006;97:640–6.
[20] de Klaver MJ, Buckingham MG, Rich GF. Lidocaine attenuates cytokine-induced cell injury in endothelial and vascular smooth muscle cells. Anesth Analg 2003;97:465–70.
[21] Leffler A, Reiprich A, Mohapatra DP, et al. Use-dependent block by lidocaine but not amitriptyline is more pronounced in tetrodotoxin (TTX)-Resistant Nav1.8 than in TTX-sensitive Na+ channels. J Pharmacol Exp Ther 2007;320:354–64.
[22] Amir R, Argoft CE, Bennett GJ, et al. The role of sodium channels in chronic inflammatory and neuropathic pain. J Pain 2006;7:51–29.
[23] Viola V, Newnham HH, Simpson RW. Treatment of intractable painful diabetic neuropathy with intravenous lignocaine. J Diabetes Complications 2006;20:34–9.
[24] Aslam A, Singh J, Rajbhandari S. An observational study on lignocaine infusion for intractable chronic pain. J Pain Relief 2016;5:255.
[25] Jaffe RA, Rowe MA. Subanesthetic concentrations of lidocaine selectively inhibit a nociceptive response in the isolated rat spinal cord. Pain 1995;60:167–74.
[26] Jaffe RA, Rowe MA. Differential nerve block. Direct measurements on individual myelinated and unmyelinated dorsal root axons. Anesthesiology 1996;84:1455–64.
[27] Challapalli V, Tremont-Lukats IW, McNicol ED, et al. Systemic administration of local anesthetic agents to relieve neuropathic pain. Cochrane Database Syst Rev 2005;4:CD003345.
[28] Kranke P, Jokinen J, Pace NL, et al. Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery. Cochrane Database Syst Rev 2015;7:CD009642.
[29] Park CH, Jung SH, Han CG. Effect of intravenous lidocaine on the neuropathic pain of failed back surgery syndrome. Korean J Pain 2012;25:94–8.
[30] Sahai El S. A comparative study of effect of intravenous lidocaine infusion, gabapentin and their combination on postoperative analgesia after thyroid surgery. Open J Anaesthesiol 2017;7:296–314.